Treating Advanced Peritoneal Mesothelioma with Spray-On Oxaliplatin

advanced peritoneal mesothelioma

European doctors have tested a new spray-on cancer drug that could be another treatment option for people with advanced peritoneal mesothelioma. The drug is oxaliplatin. It is sold under the brand name Eloxatin. It is normally given by injection into a vein. But that can cause serious side effects, including stomach pain. A new study published in the European Journal of Surgical Oncology suggests there may be a more effective way to get the benefits of oxaliplatin. Researchers found that using it as a spray for advanced peritoneal mesothelioma extended survival with fewer side effects. PIPAC for Advanced Peritoneal Mesothelioma As Surviving Mesothelioma first reported last spring, pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new way to deliver cancer medicines. … Continue reading Treating Advanced Peritoneal Mesothelioma with Spray-On Oxaliplatin »

Ofev Shelved as a Treatment for Pleural Mesothelioma

Treatment for pleural mesothelioma

It is official – the VEGF inhibitor Ofev is out of the running as a treatment for pleural mesothelioma. Hopes had been high for this drug after initial results showed a survival advantage. For the last two years, Ofev (nintedanib) was the subject of a large, international clinical trial. But now the leaders of that trial have published their Phase III trial results in The Lancet: Respiratory Medicine. They show that Ofev did not extend survival and is not an effective treatment for pleural mesothelioma. Why Hopes Were High for Ofev Ofev is an oral medication that stops cancer cells from producing a protein called VEGF. VEGF promotes the growth of blood vessels that help mesothelioma tumors grow. VEGF may … Continue reading Ofev Shelved as a Treatment for Pleural Mesothelioma »

Combination Mesothelioma Therapy Begins Pivotal Trial

mesothelioma treatment combination

A combination mesothelioma therapy that showed promise in early trials is finally being studied on a larger scale. The power-packed chemo-immuno-gene therapy known as TR002 has the potential to change the outlook for thousands of malignant mesothelioma patients. A small trial of the combination mesothelioma therapy in 2016 produced “significantly higher” mesothelioma survival rates than most patients are told to expect. Drug company Trizell announced last month that the combination will now be tested on 300 patients at sites in the US, Europe, Australia and Russia. Combination Mesothelioma Therapy Starts with Gene Therapy TR002 is an investigational gene therapy for mesothelioma patients who have failed first-line chemotherapy. This combination mesothelioma therapy is based on the human interferon-alpha 2b gene. The … Continue reading Combination Mesothelioma Therapy Begins Pivotal Trial »

New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy

mesothelioma clinical trial of dendritic cells

A Dutch company has recruited the first patients into a pivotal mesothelioma clinical trial of autologous dendritic cells. Dendritic cells are immune system cells that work as messengers. They help tell T cells to attack cancers like malignant mesothelioma. The new mesothelioma clinical trial will test using the patient’s own dendritic cells (autologous cells) as a way to keep cancer from coming back after mesothelioma treatment. Expanding Mesothelioma Treatment Options There is only one approved treatment for malignant pleural mesothelioma. This “standard of care” treatment is chemotherapy with Alimta (pemetrexed) and cisplatin. Although most mesothelioma patients receive this treatment, very few live longer than a year after diagnosis. A Netherlands-based company called Amphera is trying to change those odds. Its … Continue reading New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy »

PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma

mesothelioma immunotherapy response

A new study suggests that drugs known as PARP inhibitors may enhance immunotherapy response in mesothelioma patients. According to a report published in the Journal of Clinical Investigations, PARP inhibitors worked especially well in cancers with mutations in their DNA repair genes. Some malignant mesothelioma patients have mutated DNA repair genes. In these patients, a PARP inhibitor may modify immunotherapy response, making drugs like Keytruda work better. How PARP Impacts Immunotherapy Response PARP stands for poly (ADP-ribose) polymerase. It represents a family of proteins involved in a number of cellular processes, including DNA repair. PARP is also involved in apoptosis, or programmed cell death. Olaparib (Lynparza) is an example of a PARP inhibitor. PARP inhibitors attack tumors that already have … Continue reading PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma »

Defactinib Fails Again as a Maintenance Therapy for Mesothelioma

patient chemotherapy for mesothelioma

There has been another setback for a drug that showed promise as a maintenance therapy for mesothelioma. Defactinib is a focal adhesion kinase (FAK) inhibitor. FAK is a signaling pathway that allows stem cells to give rise to new cancer cells. The developers of defactinib hoped that FAK inhibition would help keep mesothelioma tumors from growing back after chemotherapy. But a team of international researchers has once again concluded that the drug does not work as a maintenance therapy for mesothelioma. In Search of a Maintenance Therapy for Mesothelioma Malignant pleural mesothelioma is an aggressive cancer that is very hard to treat. Standard chemotherapy drugs like pemetrexed, cisplatin, gemcitabine and vinorelbine can sometimes shrink tumors, but they usually come back. Doctors … Continue reading Defactinib Fails Again as a Maintenance Therapy for Mesothelioma »

New Mesothelioma Drug Trial Begins

mesothelioma drug trial

A new mesothelioma drug trial is now underway. The trial will test a brand new type of immunotherapy medication called CA-170. CA-170 is designed to block an immune system suppressor called VISTA. It is the only VISTA-blocking medication currently in clinical trial. “CA-170 has demonstrated favorable safety and tolerability as well as preliminary anti-tumor activity in patients across multiple tumor types,” the company said in a statement. Mesothelioma Drug Trial Focuses on VISTA Malignant mesothelioma is highly resistant to standard cancer treatments. Many top researchers believe that immunotherapy drugs offer the best promise for curing mesothelioma. That is because cancers like malignant mesothelioma survive in part by evading detection by the immune system. They do this in a variety ways … Continue reading New Mesothelioma Drug Trial Begins »

MIT Study Could Open Door for Inhalable Mesothelioma Treatment

inhalable mesothelioma treatment tested on lab mice

New lung cancer research might help pave the way for an inhalable mesothelioma treatment. MIT cancer researchers teamed up with chemical engineers to test a new method for delivering genetic instructions to lung cells. Mice that inhaled a formula designed to “tell” their lung cells to produce more of a certain protein did exactly that. The team says it’s proof that this could be a viable method for treating cancer in the lungs. Pleural mesothelioma is a lung-related cancer caused by inhaled asbestos. How Would an Inhalable Mesothelioma Treatment Work? The study was led by scientists at MIT’s Koch Center for Integrative Cancer Research. It is based on two things scientists already know about cancer treatment. One is that inhalation … Continue reading MIT Study Could Open Door for Inhalable Mesothelioma Treatment »

Survival After Mesothelioma Surgery Could Rise with Immunotherapy Spray

improving survival after mesothelioma surgery

A spray-on immune booster may one day improve survival after mesothelioma surgery. UCLA scientists tested the biodegradable spray gel in mice with advanced melanoma. They found that it stopped cancer recurrence after surgery in about half of the lab animals tested. “Around 90 percent of people with cancerous tumors end up dying because of tumor recurrence or metastasis,” says lead investigator Zhen Gu. “Being able to develop something that helps lower this risk for this to occur and has low toxicity is especially gratifying.” Gu is a professor of bioengineering and a member of the UCLA Jonsson Comprehensive Cancer Center where the spray was developed. Survival After Mesothelioma Surgery Survival after mesothelioma surgery or any other kind of cancer operation … Continue reading Survival After Mesothelioma Surgery Could Rise with Immunotherapy Spray »

Immunotherapy for Peritoneal Mesothelioma: New Drug Trial Begin

immunotherapy for peritoneal mesothelioma

Researchers in Maryland and Missouri have started human testing of a new type of immunotherapy for peritoneal mesothelioma. If the human trial of this new CAR T-cell therapy goes as well as the laboratory tests, this could be good news for many people with asbestos cancer. CAR stands for chimeric antigen receptor. CAR T-cell therapy works by “reprogramming” a patient’s immune system to fight cancer cells. Tests show this therapy can work well for blood-based cancers like leukemia. But the results have not been as good for solid tumors like peritoneal mesothelioma. MaxCyte is the American company than makes the new drug. They are hoping that their approach to immunotherapy for peritoneal mesothelioma will be better. Preparing CAR T-cell Therapy … Continue reading Immunotherapy for Peritoneal Mesothelioma: New Drug Trial Begin »

Get your free copy of
“Surviving Mesothelioma” Today!